

SEC. 2232. VACCINE DISTRIBUTION PLANS.

Section 319A of the Public Health Service Act (42 U.S.C. 247d–1) is amended—

(1) in subsection (a)—

(A) by inserting “, or other federally purchased vaccine to address another pandemic” before the period at the end of the first sentence; and

(B) by inserting “or other pandemic” before the period at the end of the second sentence; and

(2) in subsection (d), by inserting “or other pandemics” after “influenza pandemics”.

42 USC
247d–12.

SEC. 2233. COORDINATION AND COLLABORATION REGARDING BLOOD SUPPLY.

The Secretary of Health and Human Services, or the Secretary’s designee, shall—

(1) ensure coordination and collaboration between relevant Federal departments and agencies related to the safety and availability of the blood supply, including—

(A) the Department of Health and Human Services, including the Office of the Assistant Secretary for Health, the Centers for Disease Control and Prevention, the Food and Drug Administration, the Office of the Assistant Secretary for Preparedness and Response, the National Institutes of Health, the Centers for Medicare & Medicaid Services, and the Health Resources and Services Administration;

(B) the Department of Defense; and

(C) the Department of Veterans Affairs; and

Consultation.

(2) consult and communicate with private stakeholders, including blood collection establishments, health care providers, accreditation organizations, researchers, and patients, regarding issues related to the safety and availability of the blood supply.

SEC. 2234. SUPPORTING LABORATORY CAPACITY AND INTERNATIONAL COLLABORATION TO ADDRESS ANTIMICROBIAL RESISTANCE.

Section 319E of the Public Health Service Act (42 U.S.C. 247d–5) is amended—

(1) by redesignating subsections (k), (l), and (m) as subsections (m), (n), and (o), respectively; and

(2) by inserting after subsection (j), the following:

“(k) NETWORK OF ANTIBIOTIC RESISTANCE REGIONAL LABORATORIES.—

“(1) IN GENERAL.—The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall, as appropriate, maintain a network of antibiotic resistance laboratory sites to ensure the maintenance of appropriate capabilities, within existing laboratory capacity maintained or supported by the Centers for Disease Control and Prevention, to—

“(A) identify and monitor the emergence and changes in the patterns of antimicrobial-resistant pathogens;

“(B) detect, identify, confirm, and isolate such resistant pathogens, including, as appropriate, performing such